The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.
Following the launch of GenoVic last year, the organization is working to get more centers on the platform and figure out its role in an A$500M national initiative.
Using RNA sequence data from the Cancer Genome Atlas and the Chinese Glioma Genome Atlas, researchers identified six genes with expression ties to overall survival.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
A brief recap of Genetics/Genomics news the week of Feb 22, 2019: HTG Molecular, Lucid Diagnostics, Theradiag, and Xifin
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The company received Chinese regulatory approval for a lung cancer assay last year and plans to seek approval for a liquid biopsy test this year.
An Australian research team found that population genetic screening for hereditary cancer and for carrier status could be cost-effective.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.